Having trouble accessing articles? Reset your cache.

Fosbretabulin: Phase II/III data

OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif.
Product: Fosbretabulin ( Combretastatin A4P, Zybrestat))
Business: Cancer
Molecular target: Tubulin
Description: A4 prodrug phosphatase-activated tumor vascular targeting agent
Indication:

Read the full 274 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE